Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers
Launched by YALE UNIVERSITY · Apr 15, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how live music can help people with early Alzheimer's Disease, dementia, or mild cognitive impairment (MCI), along with their caregivers. The study will look at how listening to music affects heart rate, brain activity, and feelings of anxiety for both the patients and their caregivers. Participants will enjoy preferred and improvised music performed by professional musicians while their heart rates and brain activity are monitored. Through this, researchers hope to understand the positive effects of music on both the individuals with cognitive challenges and those who care for them.
To participate, individuals must be diagnosed with early Alzheimer's, mild dementia, or MCI, and their caregivers are also welcome. Participants should be willing to wear special devices to monitor heart rates and brain activity, and they will need to answer survey questions and may be recorded during the sessions. This study is currently recruiting participants aged between 18 and 92, and it aims to gather insights that could improve the quality of life for both patients and caregivers through the power of music.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical Dementia Rating 0.5 - 2
- • Be a person with or caregiver to a person with a diagnosis of early Alzheimer's Disease, mild dementia, and/or mild cognitive impairment (MCI)
- • Able to provide informed consent
- • Willing to wear an EEG headset and heart rate monitoring devices
- • Willing to possibly have small patches of body / facial hair shaved to accommodate administration of heart rate monitoring devices
- • Willing to answer survey questions about topics related to the study
- • Willing to be audio / video recorded
- Exclusion Criteria:
- • Clinical Dementia Rating \<0.5 or \> 2
- • Unable to provide informed consent
- • Endorsing suicidal ideation (SI), self-injurious behavior, or homicidal ideation (HI) above the threshold defined in the "Risk Reduction and Safety Plan"
- • Participating in another clinical trial studying AD and/or Dementia
- • Starting a new prescription medication in the last 6 months
- • Prescribed Benzodiazepines on an as needed basis
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
AZA Allsop, MD, PhD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported